Porcine pseudorabies virus, vaccine composition and preparation method and use thereof

Abstract

Provided in embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic peptide vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.

1 - 14 . (canceled) 
     
     
         15 . A nucleotide sequence substantially encoding the protein as shown in SEQ ID NO. 1 of the sequence listing. 
     
     
         16 . A nucleotide sequence substantially encoding the protein as shown in SEQ ID NO.2 of the sequence listing. 
     
     
         17 . A nucleotide sequence substantially encoding the protein as shown in SEQ ID NO. 3 of the sequence listing. 
     
     
         18 . A porcine pseudorabies virus strain comprising gD glycoprotein encoded by the nucleotide sequence as shown in SEQ ID NO.4 of the sequence listing. 
     
     
         19 . The pseudorabies virus strain as described in  claim 18 , wherein said pseudorabies virus strain comprises gB glycoprotein encoded by the nucleotide sequence shown in SEQ ID NO.5 of the sequence listing. 
     
     
         20 . The pseudorabies virus strain as described in  claim 19 , wherein said pseudorabies virus strain is the HN1201 strain or culture thereof, of which the accession number is CCTCC NO. V 201311; said HN1201 strain was deposited in the China Center for Type Culture Collection (CCTCC) on May 20, 2013, of which the address is Wuhan University, Wuhan City, Hubei Province. 
     
     
         21 . A vaccine composition, comprising an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic peptide vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain as described in  claim 18 . 
     
     
         22 . The vaccine composition as described in  claim 21 , wherein said vaccine composition comprising an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic peptide vaccine, or genetically engineered vaccine of said PRV HN1201 strain or culture thereof. 
     
     
         23 . The vaccine composition as described in  claim 22 , wherein said vaccine composition comprises an inactivated vaccine of the PRV HN1201 strain or culture thereof, of which the concentration is not less than 10 6.0  TCID 50 /ml. 
     
     
         24 . The vaccine composition as described in  claim 22 , wherein said vaccine composition comprises 25˜100 μg/dose gD protein antigen of the PRV HN1201 strain or culture thereof. 
     
     
         25 . The vaccine composition as described in  claim 21 , wherein said vaccine composition further comprises medium, adjuvants and excipient. 
     
     
         26 . A method for preparing said vaccine composition as described in  claim 22 , comprising the steps: the PRV HN1201 strain is amplified and cultured, inactivated, and then added with adjuvants and mixed thoroughly. 
     
     
         27 . A method for preparing said vaccine composition as described in  claim 22 , comprising the steps: (1) cloning said PRV recombinant gD gene; (2) expressing said PRV recombinant gD protein; and (3) mixing said PRV gD protein antigen with adjuvants based on certain ratio and emulsifying the resulting mixture.